Skip to main content

Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.

Publication ,  Journal Article
Ward, JF; Moul, JW
Published in: Curr Opin Urol
May 2005

PURPOSE OF REVIEW: Through the prostate-specific antigen era, the proportion of men less than 55 years old with newly diagnosed prostate cancer more than doubled to almost 15%. As increasing numbers of men are living longer with prostate cancer, larger proportions will eventually present to our collective practices with rising prostate-specific antigen levels. Such prostate-specific antigen relapses, conservatively estimated to affect approximately 50 000 men each year, have become the most common form of advanced prostate cancer in the current period. RECENT FINDINGS: Increasing evidence suggests that early hormonal therapy improves progression-free survival and may alter the cancer-specific survival. However, there is a cost to pay in side-effects when androgen deprivation is administered over prolonged periods. The non-steroidal anti-androgen bicalutamide may offer an equivalent progression-free survival to castration without the complications of androgen deprivation. Observational data seem to indicate that high-risk individuals (i.e. those with high-grade, high-stage disease or a prostate-specific antigen doubling time less than 12 months) may also receive benefit from early therapy. SUMMARY: The definition of advanced prostate cancer has changed. Multimodal therapy improves cancer-specific outcomes especially in men with high-risk disease. The potential opportunities for novel therapeutic agents with low associated morbidity are great.

Duke Scholars

Published In

Curr Opin Urol

DOI

ISSN

0963-0643

Publication Date

May 2005

Volume

15

Issue

3

Start / End Page

187 / 195

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Tosyl Compounds
  • Salvage Therapy
  • Risk Assessment
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Nitriles
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ward, J. F., & Moul, J. W. (2005). Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol, 15(3), 187–195. https://doi.org/10.1097/01.mou.0000165553.17534.e3
Ward, John F., and Judd W. Moul. “Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.Curr Opin Urol 15, no. 3 (May 2005): 187–95. https://doi.org/10.1097/01.mou.0000165553.17534.e3.
Ward, John F., and Judd W. Moul. “Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.Curr Opin Urol, vol. 15, no. 3, May 2005, pp. 187–95. Pubmed, doi:10.1097/01.mou.0000165553.17534.e3.

Published In

Curr Opin Urol

DOI

ISSN

0963-0643

Publication Date

May 2005

Volume

15

Issue

3

Start / End Page

187 / 195

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Tosyl Compounds
  • Salvage Therapy
  • Risk Assessment
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Nitriles
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Male